RT Journal Article
SR Electronic
T1 The Long and Winding Road for Breast Cancer Biomarkers to Reach Clinical Utility
JF Clinical Cancer Research
JO Clin Cancer Res
FD American Association for Cancer Research
SP 5543
OP 5545
DO 10.1158/1078-0432.CCR-20-2451
VO 26
IS 21
A1 Hunter, Natasha B.
A1 Kilgore, Mark R.
A1 Davidson, Nancy E.
YR 2020
UL http://clincancerres.aacrjournals.org/content/26/21/5543.abstract
AB Tumor data from the ABCSG 5 trial of chemotherapy versus endocrine therapy for premenopausal ER+ breast cancer supports molecular subtyping by Ki-67 IHC as a prognostic marker. But while this tissue was handled uniformly, Ki-67 testing overall is unstandardized, complicating clinical utility. Increasing potential biomarkers herald more challenges in biomarker validation.See related article by Bago-Horvath et al., p. 5682